NEOK Bio Launches with $75 Million Series A funding to Advance Next-Gen Bispecific ADC in Oncology November 10, 2025
First Patient Dosed in Randomized Dose Optimization Cohort of Ph 2 Study of Muzastotug + KEYTRUDA in MSS-CRC November 10, 2025
77.8% Three-Month Complete Response Rate Reported from Ph 3 UTOPIA Trial of UGN-103; FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Received November 10, 2025
Merck Enters Research & Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT) November 10, 2025
Development of UGN-301 (zalifrelimab) to discontinue following completion of Ph 1 dose escalation study November 10, 2025
FAILED TRIAL: Ph 3 ASCENT-07 study of Trodelvy® (sacituzumab govitecan-hziy) vs chemo in 1L HR+/HER2-neg metastatic breast cancer patients did not meet the primary endpoint of PFS November 10, 2025
IntoCell and Xcellon Biologics Announce MOU to Expand Access to Next-Generation ADC Technologies November 10, 2025
Nona Biosciences Announces Expansion of Collaboration with Umoja Biopharma to Advance In Vivo CAR-T Cell Therapies November 10, 2025
Dispatch Bio Announces Clinical Supply and Collaboration Agreement with BMS in Solid Tumors November 10, 2025
Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 in “NEO-CYT” trial in High-Risk, Surgically Resectable Neoadjuvant Stage III Melanoma November 10, 2025
Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors November 10, 2025
Enrollment Completed in SAFFRON Ph 3 Trial of ORPATHYS + TAGRISSO Combo in TAGRISSO-treated EGFRm, MET-overexpressed and/or amplified LA/M NSCLC patients November 10, 2025
Following discussion with FDA, safusidenib vs vorasidenib trial in grade 2 IDH1-mutant glioma cancelled November 10, 2025
Positive Data from ANTLER Ph 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010) Announced November 10, 2025
